Immuron Limited (AU:IMC) has released an update.
Immuron Limited, an Australian biopharmaceutical company, announced that CEO Steven Lydeamore will present at Sharewise on July 9, 2024, discussing Travelan sales growth and the clinical program for Clostridioides difficile, as well as upcoming company milestones. The interactive presentation will be available via live webinar, with a Q&A session allowing direct communication with Lydeamore. Immuron specializes in oral antibodies for infectious diseases, with products like Travelan aimed at preventing travelers’ diarrhea.
For further insights into AU:IMC stock, check out TipRanks’ Stock Analysis page.
